Bayer BAYRY announced that it has acquired the exclusive marketing rights for cardiovascular candidate acoramidis in Europe from BridgeBio BBIO. The rights were acquired from Eidos Therapeutics Inc., ...
Source LinkBayer BAYRY announced that it has acquired the exclusive marketing rights for cardiovascular candidate acoramidis in Europe from BridgeBio BBIO. The rights were acquired from Eidos Therapeutics Inc., ...
Source Link
Comments